GeneReach Biotechnology Corp. (TPEX:4171)
17.35
-0.20 (-1.14%)
Aug 26, 2026, 1:30 PM CST
GeneReach Biotechnology Revenue
GeneReach Biotechnology had revenue of 60.03M TWD in the quarter ending June 30, 2026, with 10.14% growth. This brings the company's revenue in the last twelve months to 238.08M, up 6.10% year-over-year. In the year 2025, GeneReach Biotechnology had annual revenue of 232.74M with 12.71% growth.
Revenue (ttm)
238.08M
Revenue Growth
+6.10%
P/S Ratio
4.18
Revenue / Employee
n/a
Employees
n/a
Market Cap
994.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 232.74M | 26.25M | 12.71% |
| Dec 31, 2024 | 206.49M | -18.97M | -8.41% |
| Dec 31, 2023 | 225.46M | -524.56M | -69.94% |
| Dec 31, 2022 | 750.02M | -262.06M | -25.89% |
| Dec 31, 2021 | 1.01B | 155.04M | 18.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 709.37M |
| Meribank Biotech | 408.48M |
| TCI GENE | 251.39M |
| NatureWise Biotech & Medicals | 174.62M |
| Lukas Biomedical | 170.01M |
| Enimmune | 53.45M |
| Holy Stone Healthcare | 47.51M |